Article: Clinical and commercial outsourcing

The demand for biologics and high potent medicines is forcing the industry to consider alternatives, such as outsourcing and integrated solutions.

The biopharmaceutical landscape is evolving rapidly. Due to the growth in injectable dosage forms, as well as highly potent solid oral medicines, outsourcing the clinical and commercial supply of these precision therapies will become highly specialised. As such, drug developers must take into account many considerations when selecting a CDMO partner, some of which are outlined in this article.